TENDER PAR-25-101

Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)

Grant opportunity Other Open Published 30 December 2024 Closing 11 August 2027

<p>The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is sparse or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant preceden

Tender details

Reference
PAR-25-101
Issuing organisation
Not recorded
Opportunity type
Grant opportunity
Industry
Other
Location
Not recorded
Closing date
11 August 2027
Document deadline
Not stated
Bid security
Not stated
Source
Grants.gov opportunity search API
Language
en
Source-reported status
Posted (as of 18 November 2026)
Status from closing date
Open (11 August 2027)

Source excerpt

Open official source
Opportunity number: PAR-25-101 Title: Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) Agency: National Institutes of Health Status: POSTED Posting date: 2024-12-30 Application response date: 2027-08-11 Description: <p>The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly in

Verified against the retrieved official source recorded as document DOC-US-0027. SHA-256 ee8d92c3fce534b5303b9f81ab3508942cd0bbd71116faf624fb206d3c8747b5 (checksum scope: source response).

National Institutes of Healthgrantgrants.govprocurement

Request a correction Back to all tenders